Previous 10 | Next 10 |
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Biosc...
Twist Bioscience (NASDAQ:TWST) announced a proposed $200M underwritten public offering of shares. TWST intends to grant the underwriters a 30-day option to purchase up to $30M of shares. Net proceeds, along with existing cash, will be used to scale its investment in its R&D organizat...
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe C2i to integrate Twist’s library preparation kits into minimal re...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Eleven Therapeutics, a company leading the AI revolution in nucleic acid therapies, today announced that they have ...
Twist Bioscience Corporation (TWST) Q1 2022 Earnings Conference Call February 4, 2022 8:00 AM ET Company Participants Angela Bitting – Senior Vice President-Corporate Affairs and Chief ESG Officer Emily Leproust – Chief Executive Officer and Co-Founder Jim Thorburn – Chie...
Although Twist Biosciences (TWST -2.2%) earlier today raised its expected revenue range for FY 2022, shares are not responding. For FY 2022, revenue is now expected to be in the range of $189 million to $198 million vs. $180.3M consensus. In its FQ1 22 results, Twist reported that orders incr...
Gainers: IRadimed IRMD +8%. Meridian Bioscience VIVO +8%. Biofrontera (NASDAQ:BFRI) +6%. Inspira Technologies Oxy (NASDAQ:IINN) +6%. Taysha Gene Therapies (NASDAQ:TSHA) +5%. Losers: Lannett Company (NYSE:LCI) -24%. Vanda Pharmaceuticals (NASDAQ:VNDA) -22%. E...
Twist Bioscience press release (NASDAQ:TWST): Q1 GAAP EPS of -$0.91. Revenue of $42M (+48.9% Y/Y). Orders Increased 48% to $49.6M For the full fiscal year 2022: Revenue is now expected to be in the range of $189 million to $198 million vs. $180.3M consensus. Gross margin is expected to be bet...
-- Record Revenues of $42M; Increase of 49% over $28.2M in Fiscal 2021 -- -- Orders Increased 48% to $49.6M -- -- Increased Revenue Guidance for Fiscal 2022 -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of hi...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...